New York-based Regeneron Pharmaceuticals, manufacturer and seller of the macular degeneration drug Eylea, is being sued by the Department of Justice (DOJ) for allegedly flouting Medicare’s price reporting requirements.
Regeneron failed to report applicable price concessions in the form of credit card processing fees to the Centers for Medicare and Medicaid Services (CMS), the DOJ claimed in a press release Wednesday.
